2024 Nasdaq atai - With a Buy rating, Baader Helvea initiated coverage on ATAI Life Sciences NV (NASDAQ:ATAI). The price target seems to have been set at $21.00 for ATAI Life Sciences. The stock has a 52-week-high ...

 
NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health .... Nasdaq atai

Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically …Atai Life Sciences N.V. (Nasdaq: ATAI) announced positive initial results for their Phase 1 clinical trial of KUR-101. KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD).The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated coverage of ATAI Life Sciences N.V. (NASDAQ:ATAI) with a Buy recommendation. Analyst Price Forecast Suggests 605.71% Upside. As ...31dfe48811d2.q4INGxiFDVnmwbNEPLSmjL3zAvKTd4nY4VaO5TL8Qr4.wrRFckjAe2GI7PA3U4fK …Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs.The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...Atai Life Sciences (NASDAQ: ATAI) $1.12 (7.7%) $0.08 Price as of December 1, 2023, 4:00 p.m. ET Overview News & Analysis Financial Health Valuation Related Stocks Key Data …Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...(Part four of a four-part series) See previous stories in this series: Insider's Peek At Mammoth Of Psychedelics VCs, Palo S...Atai Life Sciences ( NASDAQ: ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them. It ...Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Investors In Q2 2023: 7. Atai Life Sciences N.V. (NASDAQ:ATAI) is a biotechnology company developing treatments for mental health disorders.ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders.The company has recently garnered ...Nov 24, 2023 · The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. ... (NASDAQ: ATAI) reported its financial results and corporate updates for ... atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains …May 11, 2023 · The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... October 6, 2023. NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau... atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ...The latest price target for ATAI Life Sciences ( NASDAQ: ATAI) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 20.00 expecting ATAI to rise ...One of the key developments in the psychedelic industry over the past year and a half has been the stock market debut of companies like Atai Life Sciences N.V. (NASDAQ: ATAI), the German biopharma ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...-5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.More from Bloomberg. Stock analysis for ATAI Life Sciences NV (ATAI:NASDAQ GM) including stock price, stock chart, company news, key statistics, …(RTTNews) - atai Life Sciences N.V. (ATAI) reported additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. KUR-101 was well tolerated and showed ...EVgo, Inc. (NASDAQ:EVGO) fell 14.3% to close at $16.19 following negative analyst coverage from Credit Suisse. Atai Life Sciences N.V. (NASDAQ:ATAI) dropped 13.8% to close at $12.85 following Q3 ...Shares in Peter Thiel-backed psychedelic start-up Atai Life Sciences jumped Friday on their first day of trading on Wall Street. The newly listed Nasdaq stock opened up 40% before pulling back some.Nov 24, 2023 · The latest ATAI Life Sciences stock prices, stock quotes, news, and ATAI history to help you invest and trade smarter. ... (NASDAQ: ATAI) reported its financial results and corporate updates for ... Atai Life Sciences B.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the pricing of its upsized ...atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET.NEW YORK and BERLIN, Aug. 10, 2023-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 ...On March 30, atai Life Sciences N.V. (NASDAQ: ATAI) reported fourth-quarter and full-year 2021 financial results and R&D progress. The clinical-stage biopharma company also highlighted strategic ...Alcohol use disorder. Treatment-resistant depression. Opiate withdrawal syndrome. PTSD. Social anxiety in autistic adults. Anxiety with a life-threatening illness. Generalized anxiety disorder ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...BEIJING, Aug. 06, 2019 (GLOBE NEWSWIRE) -- ATA Inc. ("ATA" or the "Company", Nasdaq: ATAI), a company focused on providing students with quality educational experiences and services in China and ...atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).Jul 14, 2021 · Some of the companies already making a big splash in the as yet small sector include COMPASS Pathways plc (NASDAQ: CMPS), Atai Life Sciences N.V. (NASDAQ: ATAI), and Seelos Therapeutics, Inc ... atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET.Oct 5, 2022 · - atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ... NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical … See moreNEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical … See moreNEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical … See moreatai Life Sciences, (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, visits the Nasdaq MarketSite in Times Square.ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...-5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...Oct 2, 2023 · NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...Alnylam currently trades on the NASDAQ with a nearly $15 billion market capitalization, justifying Angermayer’s net worth of $700 million. Florian Brand, the co-founder and current CEO of ATAI Life Sciences, comes with a successful entrepreneurial background in the online retail industry.NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming …NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Atai Life Sciences (NASDAQ:ATAI) $215.8 million Developing multiple drugs based on psychedelic substances, including ibogaine and ketamine. Compass Pathways (NASDAQ:CMPS) $350.9 millionFind the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. ... Nasdaq Insider Activity page provides trading information of corporate insiders (officers ...Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Atai Life Sciences N.V. (NASDAQ:ATAI) was down, falling 38% to $1.63 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, the company announced that the Food and Drug Administration (FDA) gave the company Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R …8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...Find the latest SEC Filings data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.atai ended the second quarter of 2022 with a cash position of $312 million, which combined with committed funding from Hercules loan facility is anticipated to provide cash runway into 2025. Cash ...Real time Atai Life Sciences (ATAI) stock price quote, stock graph, news & analysis.NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...On September 27, ATAI Life Sciences (NASDAQ:ATAI), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of PTSD and other indications, announced ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...Through its subsidiary Perception Neuroscience, atai Life Sciences N.V. (NASDAQ:ATAI) recently released an update on another platform for treatment resistant depression (TRD) that's derived from a ...Nov 17, 2023 · Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ... (NASDAQ: ATAI) Atai Life Sciences Nv's forecast annual revenue growth rate of 69.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.63%.8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...Shares of Atai Life Sciences B.V. (ATAI.O), backed by billionaire investor Peter Thiel, surged 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market ...Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ...View the latest ATAI Life Sciences N.V. (ATAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.In addition to the previously announced presence of comedians Eric Andre and Reggie Watts, featured speakers include atai Life Sciences’ (NASDAQ:ATAI) founder and chairman Christian Angermayer; ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...Oct 2, 2023 · NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... Therefore, something I will be watching closely is whether companies like MindMed, Compass, and atai Life Sciences (NASDAQ:ATAI) can win back some of their lost market caps.Nasdaq atai

Over the past 3 months, 7 analysts have published their opinion on ATAI Life Sciences (NASDAQ:ATAI) stock. These analysts are typically employed by large Wall Street banks and tasked with .... Nasdaq atai

nasdaq atai

May 25, 2023 · ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ... NEW YORK and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...Atai Life Sciences (NASDAQ:ATAI) closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.)Atai Life Sciences (NASDAQ:ATAI) $215.8 million Developing multiple drugs based on psychedelic substances, including ibogaine and ketamine. Compass Pathways (NASDAQ:CMPS) $350.9 millionNov 29, 2023 · According to 4 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 1,110.76% from the latest price. Palm Beach, FL – July 27, 2022 - For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam war and is still the preferred anesthetic in battlefield situations. It can be used to induce a kiFind the latest Insider Activity data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...Nov 14, 2023 · NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX.Nov 15, 2021 · The atai Impact program will be initially funded by 1% of the gross proceeds from our June 2021 IPO and founders’ and shareholders’ contributions. Third Quarter 2021 Financial Results. Cash ... On September 27, ATAI Life Sciences (NASDAQ:ATAI), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of PTSD and other indications, announced ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...The latest price target for . ATAI Life Sciences (NASDAQ: ATAI) was reported by HC Wainwright & Co. on August 14, 2023.The analyst firm set a price target for $20.00 …Quotes Summary Real-Time After-Hours Pre-Market Charts NEWS & ANALYSIS News Press Releases Analyst Research ATAI ATAI REAL TIME ATAI Real-Time Quotes 1D …atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.Apr 13, 2023 · NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023.For example, they have invested more money into Cybin (NYSE: CYBN) than they have into larger companies such as GH Research (Nasdaq: GHRS) and atai Life Sciences (Nasdaq: ATAI). Obviously, they expect Cybin to have larger returns.I’ve also been asked if it’s proper and ethical that COMPASS Pathways (Nasdaq: CMPS) and atai Life Sciences (Nasdaq: ATAI) own the majority of the patents around those psychedelics.“In just four years with Florian as CEO we raised more than $600 million, grew the staff to more than 100, brought eight compounds into clinical-stage trials, and took Atai public on the Nasdaq ...Clinical-stage biopharmaceutical company Atai Life Sciences (NASDAQ:ATAI) declared that it has signed a term loan agreement with Hercules Capital, Inc. for a maximum amount of $175 million.Atai Life Sciences N.V. (NASDAQ:ATAI) AVROBIO, Inc. (NASDAQ:AVRO) Axsome Therapeutics, Inc. (NASDAQ:AXSM) (communicated in its earnings release a potential delay in approval of its major ...NEW YORK and BERLIN, Aug. 10, 2023-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 ...To compile our list of the best German stocks to buy, we first made a list of all German firms that are trading on the NASDAQ and NYSE exchanges. Then, those firms with the greatest number of hedge fund investors during Q2 2023, and the top German stocks are as follows. 12 Best German Stocks To Buy Now 12. Atai Life Sciences N.V. (NASDAQ:ATAI)Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.Nov 30, 2023 · Atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine) Aug. 08: CI Atai Life Sciences N.V., Atai Life Sciences AG Enters into the Second Amendment to Loan and Security Agreement with the Several Banks May. 31: CI 111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed …On September 27, ATAI Life Sciences (NASDAQ:ATAI), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of PTSD and other indications, announced ...atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, recently announced the launch of TryptageniX.Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired …atai - encouraging results for R-ketamine As you might remember, ATAI Life Sciences AG (Nasdaq: ATAI) had a setback for R-ketamine in January this year, when the compound did not hit statistical ...NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders ...Mar 6, 2023 · NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ... 8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...Atai Life Cuts Expenses, Extends Cash Runway. Atai Life Sciences (NASDAQ: ATAI) announced fiscal second-quarter results today for the quarter ending June 30, 2022 with no revenue, but an update on expenses and cash levels. Read more here. Rubicon Organics Sales Rise as Premium Brand Grows.Benzinga. Sep. 27, 2022, 02:04 PM. Atai Life Sciences' (NASDAQ:ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC ...Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, the company announced that the Food and Drug Administration (FDA) gave the company Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R …Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ...The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ...NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more. Earnings Estimate Revisions for atai Life Sciences N.V. For the fiscal year ending December 2023, this company is expected to earn -$0.81 per share, which is a change of 17.4% from the year-ago ...8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...DarioGaona/iStock via Getty Images. Atai Life Sciences (NASDAQ:ATAI) has been making great progress in advancing several drugs from its pipeline on multiple fronts.In particular, it is advancing a ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...Benzinga. Sep. 27, 2022, 02:04 PM. Atai Life Sciences' (NASDAQ:ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC ...Instrument Name Atai Life Sciences N.V. Instrument Symbol (ATAI-Q). Instrument Exchange NASDAQ ; Previous Close 1.1200 ; 52-Week High/Low 3.6500 1.0400 ; Volume ...-5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...Nov 14, 2023 · The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ... The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ .... Airsculpt technologies